HAMBURG, Germany—Evotec AG and Harvard University have started a second strategic alliance including Brigham and Women's Hospital aimed at discovering and developing new biomarkers and treatments in the field of kidney disease.
“The primary mechanisms leading and driving the development of kidney damage have not been systematically explored," said Dr. Andy McMahon, Professor at Harvard University. “We aim to comprehensively screen for these mechanisms looking at how individual kidney cell types respond to acute and chronic insults during various stages of disease progression as well as during the recovery process."
The first successful collaboration "CureBeta" was established in March 2011 to develop new diabetes therapies targeting beta cell regeneration.
The alliance will pursue systematic and unbiased approaches towards the identification of kidney disease relevant mechanisms with particular interest in mechanisms with disease modifying potential.
